2-羟基-3-氨基-6-甲基吡啶 | 52334-79-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-羟基-3-氨基-6-甲基吡啶
• 中文别名: 4-甲氧基-N-(4-甲氧基苯基)苯磺酰胺；3-氨基-6-甲基-2(1H)-吡啶酮；3-氨基-6-甲基吡啶-2-醇
• 英文名称: 3-amino-6-methyl-pyridin-2-ol
• 英文别名: 3-Amino-6-methylpyridin-2-ol；3-amino-6-methyl-1H-pyridin-2-one
• CAS: 52334-79-9
• 化学式: C₆H₈N₂O
• mdl: MFCD07774135
• 分子量: 124.142
• InChiKey: OPTKLLIHUWHIFL-UHFFFAOYSA-N

物化性质

• 沸点：
  340.2±35.0 °C(Predicted)
• 密度：
  1.137±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-6-methylpyridin-2-ol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-6-methylpyridin-2-ol
CAS number: 52334-79-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H8N2O
Molecular weight: 124.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-羟基-3-氨基-6-甲基吡啶 在 sodium hydride 、 三乙胺 、 lithium bromide 、 O‐(1H‐benzotriazol‐1‐yl)‐N,N,N′,N′‐tetramethyluronium tetrafluoroborate 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 12.92h， 生成 N-[1,2-dihydro-1-(4'-fluorobenzyl)-6-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide
  参考文献：
  名称：

  Identification of the First Synthetic Allosteric Modulator of the CB₂ Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief

  摘要：

  The direct activation of cannabinoid receptors (CBRs) results in several beneficial effects; therefore several CBRs ligands have been synthesized and tested in vitro and in vivo. However, none of them reached an advanced phase of clinical development due mainly to side effects on the CNS. Medicinal chemistry approaches are now engaged to develop allosteric modulators that might offer a novel therapeutic approach to achieve potential therapeutic benefits avoiding inherent side effects of orthosteric ligands. Here we identify the first ever synthesized positive-allosterk modulator (PAM) that targets CB(2)Rs. The evidence for this was obtained using [H-3]CP55940 and [S-35]GTP gamma S binding assays. This finding will be useful for the characterization of allosteric binding site(s) on CB(2)Rs which will be essential for the further development of CB2R allosteric modulators. Moreover, the new CB2R PAM displayed antinociceptive activity in vivo in an experimental mouse model of neuropathic pain, raising the possibility that it might be a good candidate for clinical development.

  DOI：

  10.1021/acs.jmedchem.8b00368
• 作为产物：
  描述：

  2-羟基-6-甲基吡啶 在 水 、 硝酸 、 sodium acetate 、 钯 、 溶剂黄146 作用下， 生成 2-羟基-3-氨基-6-甲基吡啶
  参考文献：
  名称：

  Salemink; van der Want, Recueil des Travaux Chimiques des Pays-Bas, 1949, vol. 68, p. 1013,1024

  摘要：

  DOI：

文献信息

• Catalytic Reductions and Tandem Reactions of Nitro Compounds Using in Situ Prepared Nickel Boride Catalyst in Nanocellulose Solution
  作者：Kaniraj Jeya Prathap、Qiong Wu、Richard T. Olsson、Peter Dinér

  DOI：10.1021/acs.orglett.7b02090

  日期：2017.9.15

  A mild and efficient method for the in situ reduction of a wide range of nitroarenes and aliphatic nitrocompounds to amines in excellent yields using nickel chloride/sodium borohydride in a solution of TEMPO-oxidized nanocellulose in water (0.01 wt %) is described. The nanocellulose has a stabilizing effect on the catalyst, which increases the turnover number and enables low loading of nickel catalyst

  描述了一种温和有效的方法，用于在TEMPO氧化的纳米纤维素水溶液（0.01 wt％）中使用氯化镍/硼氢化钠以优异的产率将多种硝基芳烃和脂肪族硝基化合物原位还原为胺。纳米纤维素对催化剂具有稳定作用，这增加了周转次数，并使镍催化剂（0.1–0.25 mol％NiCl 2）的负载量较低。另外，开发了两个串联方案，其中将原位形成的胺用Boc保护成氨基甲酸酯，或进一步与环氧化物反应，以优异的产率产生β-氨基醇。
• HETEROCYCLIC DERIVATIVES
  申请人：Ahn Sung Oh

  公开号：US20110028467A1

  公开（公告）日：2011-02-03

  The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.

  本发明涉及杂环衍生物，更具体地，涉及用于制备治疗与尿酸相关疾病的药物的新颖杂环衍生物。
• Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogs
  作者：Jacob M. Hoffman、John S. Wai、Craig M. Thomas、Rhonda B. Levin、Julie A. O'Brien、Mark E. Goldman

  DOI：10.1021/jm00099a006

  日期：1992.10

  A potent (IC50 = 30 nM), specific nonnucleoside HIV-1 reverse transcriptase (RT) inhibitor 3-[N-(phthalimidomethyl)amino]-5-ethyl-6-methylpyridin-2(1H) -one (1), was discovered through an in vitro screening program. This compound did not inhibit (IC50 > 300 microns) other DNA and RNA polymerases, including HIV-2 RT and SIV-RT. Unfortunately, hydrolytic instability of this (aminomethyl)phthalimide precluded

  一种有效的（IC50 = 30 nM）特异性非核苷HIV-1逆转录酶（RT）抑制剂3- [N-（邻苯二甲酰亚胺甲基）氨基] -5-乙基-6-甲基吡啶-2（1H）-一（1）是通过体外筛选程序发现的。该化合物不会抑制（IC50> 300微米）其他DNA和RNA聚合酶，包括HIV-2 RT和SIV-RT。不幸的是，这种（氨基甲基）邻苯二甲酰亚胺的水解不稳定性不能用作抗病毒剂。在本系列的第一篇论文中，描述了初步开发工作，该工作生产了乙基邻苯二甲酰亚胺20，该水解稳定的化合物具有降低的HIV-1 RT抑制活性（100倍）和在H9细胞中的抗病毒活性弱（CIC95 = 40 microM）。结构活性研究表明了5-乙基的重要性，吡啶酮环上的6-甲基取代基图案以及在吡啶酮和邻苯二甲酰亚胺杂环之间需要一个灵活的两个原子的连接基。这些引线1和20为进一步开发这种抑制剂结构类型提供了基础，从中选择了几种化合物（随附报告的主题）进行临床评估。
• [EN] QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] COMPOSÉS DE QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, ET 1-AZABICYCLO[3.2.2]NONANE UTILES COMME LIGANDS DU RÉCEPTEUR ALPHA-7 NICOTINIQUE DE L'ACÉTYLCHOLINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013177024A1

  公开（公告）日：2013-11-28

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  本公开提供I式化合物，包括其盐，以及使用该化合物的组合物和方法。这些化合物是尼古丁酸α7受体的配体，可用于治疗中枢神经系统的各种疾病，尤其是情感和神经退行性疾病。
• Sirtuin modulating compounds
  申请人：Nunes J. Joseph

  公开号：US20070037809A1

  公开（公告）日：2007-02-15

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于增加细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或应激有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块性疾病，炎症，癌症和/或红斑病，以及需要增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物和另一种治疗剂的组合物。